estriol and Breast Neoplasms studies

hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.

Research Excerpts

Excerpt	Relevance	Reference
"005% estriol vaginal gel showed efficacy in improving the symptoms and signs of vulvovaginal atrophy."	9.34	Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-contr ( Campos-Delgado, M; Gil-Gil, M; Hirschberg, AL; Lidbrink, E; Nieto-Magro, C; Presa-Lorite, J; Sánchez-Rovira, P; Suárez-Almarza, J, 2020)
"005% estriol vaginal gel did not significantly influence estrogens, FSH, and LH levels in women with breast cancer receiving NSAI."	9.34	A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aroma ( Bermejo-De Las Heras, B; Gil-Gil, M; Hirschberg, AL; Nieto-Magro, C; Sánchez-Rovira, P, 2020)
"The significant decline in gonadotropin levels, indicating systemic effects, has to be kept in mind when offering vaginal estriol to breast cancer patients receiving an aromatase inhibitor."	9.15	Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. ( Fink-Retter, A; Geisendorfer, T; Glatz, C; Königsberg, R; Kubista, E; Pfeiler, G; Seifert, M; Singer, CF, 2011)
"The results confirm that estriol may block the protective effect of oral contraceptives on fibroadenomas, since we observed decreased fibroadenoma width among the group 1 patients but not the group 2 patients."	9.12	Effect of oral contraceptive with and without associated estriol on ultrasound measurements of breast fibroadenoma: randomized clinical trial. ( Baracat, EC; Estevão, RA; Nazário, AC, 2007)
"Proliferation of two oestrogen receptor-positive breast cancer cell lines (ZR 75-1 and HCC 1500) was investigated after incubation with oestrone (E₁), oestradiol (E₂), oestriol (E₃), and oestetrol (E₄)."	7.81	Oestetrol stimulates proliferation and oestrogen receptor expression in breast cancer cell lines: comparison of four oestrogens. ( Fehm, T; Liu, S; Mueck, AO; Neubauer, H; Ruan, X; Schultz, S; Seeger, H, 2015)
"We investigated the effect of a combination of vaginal ultra-low-dose estriol with lactobacilli on the sexual functioning domain of quality of life during the treatment of breast cancer survivors on an aromatase inhibitor with vaginal atrophy."	7.81	Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Mögele, M; Neven, P; Ortmann, O; Prasauskas, V, 2015)
"03 mg estriol-lactobacilli combination on the vaginal ecosystem in postmenopausal breast cancer (BC) survivors on aromatase inhibitors (AI) with severe atrophic vaginitis."	7.81	Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Neven, P; Ortmann, O; Prasauskas, V, 2015)
"Birth weight has been positively associated with breast cancer risk in adult life and is positively associated with the principal pregnancy estrogen estriol."	7.73	Maternal height, pregnancy estriol and birth weight in reference to breast cancer risk in Boston and Shanghai. ( Adami, HO; Hsieh, CC; Lagiou, A; Lagiou, P; Samoli, E; Trichopoulos, D, 2005)
"It has been hypothesized that the ratio of urinary 2-hydroxyestrone to 16alpha-hydroxyestrone (2-OHE1/16alpha-OHE1 represents a biomarker for breast cancer risk; the lower the ratio the higher the risk."	7.71	Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women. ( Bernstein, L; Gentzschein, E; London, S; Pike, MC; Stanczyk, FZ; Tseng, CC; Ursin, G; Yang, D, 2002)
"The influence of the aromatase inhibitor 4-hydroxyandrostenedione (4OHA) given intramuscularly on the peripheral aromatisation of androstenedione into oestrone was investigated in postmenopausal women with breast cancer and compared with the suppression of plasma oestradiol (E2)."	7.68	The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. ( Dowsett, M; Jacobs, S; Jones, AL; Lonning, PE; MacNeill, F; Powles, TJ, 1992)
"The action of tamoxifen was studied in two models: in breast cancer cell lines MCF-7 and R-27."	7.67	[Effect of tamoxifen and estrogens on breast cancer cell lines: MCF-7 and R-27, and on the uterus and vagina of fetal and newborn guinea-pigs]. ( Gelly, C; Giambiagi, N; Lecerf, F; Mayrand, C; Nguyen, BL; Pasqualini, JR, 1985)
"The daily excretion of estrone, estradiol, and estriol was determined for 22 normal women and 35 women with primary breast cancer."	7.66	Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer. ( Dao, TL; Lonergan, PA; Morreal, CE; Nemoto, T, 1979)
"Urine samples were analyzed for estrone (E1), estradiol (E2), and Estriol (E3) to test the hypothesis that women diagnosed with benign breast disease (high risk for breast cancer?) will have lower estriol proportions (E3/E1 + E2 + E3) than a comparison control group."	7.66	Benign breast disease: estriol proportions and family history of breast cancer. ( Elinson, L; Morgan, RW; Vakil, DV, 1981)
"Urine levels of three major estrogens and of pregnanediol were measured for 76 nulliparous daughters of breast cancer patients and for 115 control women of similar age and parity."	7.66	Elevated urine estrogen and pregnanediol levels in daughters of breast cancer patients. ( Brown, JB; Garas, J; MacMahon, B; Papaioannou, A; Trichopoulos, D, 1981)
"We have infused [6,7-3H]estrone or [6,7-3H]estradiol and [4-14C]estriol into seven women who had had breast cancer and into five normal postmenopausal women."	7.66	Estriol production rates and breast cancer. ( Longcope, C; Pratt, JH, 1978)
"The metabolism of estradiol, its production rate and the urinary excretion rate of its metabolites were studied in 5 women patients with breast cancer, 2 of whom were postmenopausal and 3 were ovariectomized, both before and after a period of 7beta,17alpha-dimethyltestosterone (calusterone) therapy."	7.65	7beta,17alpha-Dimethyltestosterone (calusterone)-induced changes in the metabolism, production rate, and excretion of estrogens in women with breast cancer: a possible mechanism of action. ( Fishman, J; Hellman, L, 1976)
"The effects of estrone, estradiol, and estriol on MCF-7 human breast cancer are compared."	7.65	Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. ( Bolan, G; Lippman, M; Monaco, ME, 1977)
"Phase I pharmacokinetic (PK) study assessed circulating estrogens in breast cancer (BC) patients on a non-steroidal aromatase inhibitor (NSAI) with vaginal atrophy using vaginal ultra-low-dose 0."	6.79	Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Moegele, M; Neven, P; Ortmann, O; Prasauskas, V, 2014)
"Mammary fibroadenoma is a disease that affects a large number of women of reproductive age."	6.73	Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial. ( Baracat, EC; Estevão, RA; Logullo, AF; Nazário, AC; Oshima, CT, 2007)
"005% estriol vaginal gel showed efficacy in improving the symptoms and signs of vulvovaginal atrophy."	5.34	Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-contr ( Campos-Delgado, M; Gil-Gil, M; Hirschberg, AL; Lidbrink, E; Nieto-Magro, C; Presa-Lorite, J; Sánchez-Rovira, P; Suárez-Almarza, J, 2020)
"005% estriol vaginal gel did not significantly influence estrogens, FSH, and LH levels in women with breast cancer receiving NSAI."	5.34	A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aroma ( Bermejo-De Las Heras, B; Gil-Gil, M; Hirschberg, AL; Nieto-Magro, C; Sánchez-Rovira, P, 2020)
"It is concluded that in the MCF-7 human mammary cancer cell line E3 and E3-3-S stimulate PR very significantly, but it is suggested that E3-3-S acts through the hydrolyzed E3."	5.27	Effect of estriol, estriol-3-sulfate and estriol-17-sulfate on progesterone and estrogen receptors of MCF-7 human breast cancer cells. ( Gelly, C; Pasqualini, JR, 1986)
" Analysis of the dose-response curves shows induction by Oe2 to be 10 times and 50 times greater than Oe3 and Oe4, respectively."	5.26	Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture. ( Bayard, F; Jozan, S; Kreitmann, B, 1981)
"The significant decline in gonadotropin levels, indicating systemic effects, has to be kept in mind when offering vaginal estriol to breast cancer patients receiving an aromatase inhibitor."	5.15	Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. ( Fink-Retter, A; Geisendorfer, T; Glatz, C; Königsberg, R; Kubista, E; Pfeiler, G; Seifert, M; Singer, CF, 2011)
"The results confirm that estriol may block the protective effect of oral contraceptives on fibroadenomas, since we observed decreased fibroadenoma width among the group 1 patients but not the group 2 patients."	5.12	Effect of oral contraceptive with and without associated estriol on ultrasound measurements of breast fibroadenoma: randomized clinical trial. ( Baracat, EC; Estevão, RA; Nazário, AC, 2007)
" Postmenopausal genital and urinary problems with recurrent infections, incontinence, and dyspareunia can effectively be treated by vaginal application of estriol, which seems to be safe for women treated for breast cancer."	4.91	Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part I. ( Comhaire, FH; Depypere, HT, 2015)
"This paper aimed to evaluate the evidence comparing bioidentical hormones, including progesterone, estradiol, and estriol, with the commonly used nonbioidentical versions of HRT for clinical efficacy, physiologic actions on breast tissue, and risks for breast cancer and cardiovascular disease."	4.85	The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? ( Holtorf, K, 2009)
"At menopause, several abnormalities in oestrogen metabolism have been reported, which may increase the likelihood of cancer development in the breast or uterus following oestrone or oestradiol-17 beta supplementation."	4.76	Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. ( Lemon, HM, 1980)
"Risk factors of breast cancer have been correlated with the availability of estradiol and estrone."	4.75	Breast cancer: potentially predisposing and protecting factors. Role of pregnancy, lactation, and endocrine status. ( Messer, RH; Vorherr, H, 1978)
" Herein, we assessed if oestrogens, including oestrone (E1), oestradiol (E2) and oestriol (E3), are associated with A-FABP in the obesity-related BC development."	3.91	A-FABP and oestrogens are independently involved in the development of breast cancer. ( Hao, J; Kong, M; Li, B; Sauter, ER; Yan, X, 2019)
"We investigated the effect of a combination of vaginal ultra-low-dose estriol with lactobacilli on the sexual functioning domain of quality of life during the treatment of breast cancer survivors on an aromatase inhibitor with vaginal atrophy."	3.81	Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Mögele, M; Neven, P; Ortmann, O; Prasauskas, V, 2015)
"Proliferation of two oestrogen receptor-positive breast cancer cell lines (ZR 75-1 and HCC 1500) was investigated after incubation with oestrone (E₁), oestradiol (E₂), oestriol (E₃), and oestetrol (E₄)."	3.81	Oestetrol stimulates proliferation and oestrogen receptor expression in breast cancer cell lines: comparison of four oestrogens. ( Fehm, T; Liu, S; Mueck, AO; Neubauer, H; Ruan, X; Schultz, S; Seeger, H, 2015)
"03 mg estriol-lactobacilli combination on the vaginal ecosystem in postmenopausal breast cancer (BC) survivors on aromatase inhibitors (AI) with severe atrophic vaginitis."	3.81	Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Neven, P; Ortmann, O; Prasauskas, V, 2015)
"1) pmol/l in AI-treated breast cancer patients, tamoxifen-treated breast cancer patients, postmenopausal controls and postmenopausal controls on vaginal estradiol, respectively."	3.78	Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients. ( Baumgart, J; Bergquist, J; Kask, K; Kunovac Kallak, T; Kushnir, MM; Moby, L; Nilsson, K; Norjavaara, E; Stavreus Evers, A; Sundström Poromaa, I, 2012)
" Serum concentrations of estriol (E3), anti-estrogen alpha-fetoprotein (AFP), and pregnancy-associated plasma protein-A (PAPP-A) were measured in 23,824 pregnant women from a separate prospective cohort, the FASTER trial."	3.78	Birth weight, breast cancer and the potential mediating hormonal environment. ( Bukowski, R; Chlebowski, RT; D'Alton, ME; Furberg, AS; Hankins, GD; Malone, FD; Thune, I, 2012)
"Salivary hormone levels of testosterone (T), Estradiol (E2), Progesterone (P), Estriol (E3), Estrone (E1), DHEAS and Cortisol (C) were measured by Enzyme Immunoassay (EIA) in 357 women with histologically verified breast cancer and 184 age-matched control women."	3.76	Low salivary testosterone levels in patients with breast cancer. ( Antsaklis, A; Dimitrakakis, C; Glaser, R; Marinopoulos, S; Tsigginou, A; Zava, D, 2010)
" We have successfully applied this technique to determine the seven estrogen conjugates in urine samples of a pregnant woman and found unique concentration changes of six estrogen conjugates at different stages of pregnancy while the concentration of estriol-3-glucuronide (E3-3G) remained constant."	3.74	Hydrophilic interaction liquid chromatography-tandem mass spectrometry determination of estrogen conjugates in human urine. ( Li, XF; Qin, F; Sawyer, MB; Zhao, YY, 2008)
" Methylnitrosourea (MNU)-exposed animals were treated with saline, E3, E2 + P, E3 + P, hCG, or were allowed to experience pregnancy, and AFP levels were measured in the serum and subsequent tumor incidence was recorded."	3.74	Hormones of pregnancy, alpha-feto protein, and reduction of breast cancer risk. ( Agarwal, A; Andersen, TT; Bennett, JA; Jacobson, HI; Lemanski, N; Narendran, A, 2008)
"Birth weight has been positively associated with breast cancer risk in adult life and is positively associated with the principal pregnancy estrogen estriol."	3.73	Maternal height, pregnancy estriol and birth weight in reference to breast cancer risk in Boston and Shanghai. ( Adami, HO; Hsieh, CC; Lagiou, A; Lagiou, P; Samoli, E; Trichopoulos, D, 2005)
"It has been suggested that a low level of the 2-hydroxyestrogen metabolites (2-OHE) and a high level of 16alpha-hydroxyestrone (16alpha-OHE1) are associated with an enhanced risk of breast cancer."	3.73	Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. ( Loft, S; Olsen, A; Overvad, K; Thomsen, BL; Tjonneland, A; Wellejus, A, 2005)
"It has been hypothesized that the ratio of urinary 2-hydroxyestrone to 16alpha-hydroxyestrone (2-OHE1/16alpha-OHE1 represents a biomarker for breast cancer risk; the lower the ratio the higher the risk."	3.71	Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women. ( Bernstein, L; Gentzschein, E; London, S; Pike, MC; Stanczyk, FZ; Tseng, CC; Ursin, G; Yang, D, 2002)
"The comparative mitogenic activities of 17beta-estradiol (E2) and four metabolites, 2-hydroxyestradiol (2-OHE2), 2-hydroxyestrone (2-OHE1), 16alpha-hydroxyestradiol (16alpha-OHE2) and 16alpha-hydroxyestrone (16alpha-OHE1) were determined in estrogen receptor (ER)-positive MCF-7 and T47D human breast cancer cells."	3.70	Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. ( Gupta, M; McDougal, A; Safe, S, 1998)
"To test the hypothesis that high levels of endogenous oestrogens increase the risk for developing breast cancer, concentrations of oestrone, oestradiol and oestriol were measured in 24 h urine samples from 1000 women participants in a prospective study of breast cancer on the island of Guernsey."	3.69	A prospective study of urinary oestrogen excretion and breast cancer risk. ( Allen, DS; Brown, JB; Bulbrook, RD; Fentiman, IS; Hermon, C; Key, TJ; Moore, JW; Pike, MC; Wang, DY, 1996)
"The influence of the aromatase inhibitor 4-hydroxyandrostenedione (4OHA) given intramuscularly on the peripheral aromatisation of androstenedione into oestrone was investigated in postmenopausal women with breast cancer and compared with the suppression of plasma oestradiol (E2)."	3.68	The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. ( Dowsett, M; Jacobs, S; Jones, AL; Lonning, PE; MacNeill, F; Powles, TJ, 1992)
"The biological effects of estriol (E3) have been studied in three estrogen targets, namely, the rat uterus in vivo and in vitro, in primary human endometrial cell cultures and in MCF-7 human breast cancer cells in culture."	3.67	Biology and receptor interactions of estriol and estriol derivatives in vitro and in vivo. ( Katzenellenbogen, BS, 1984)
"The action of tamoxifen was studied in two models: in breast cancer cell lines MCF-7 and R-27."	3.67	[Effect of tamoxifen and estrogens on breast cancer cell lines: MCF-7 and R-27, and on the uterus and vagina of fetal and newborn guinea-pigs]. ( Gelly, C; Giambiagi, N; Lecerf, F; Mayrand, C; Nguyen, BL; Pasqualini, JR, 1985)
"Urine levels of three major estrogens and of pregnanediol were measured for 76 nulliparous daughters of breast cancer patients and for 115 control women of similar age and parity."	3.66	Elevated urine estrogen and pregnanediol levels in daughters of breast cancer patients. ( Brown, JB; Garas, J; MacMahon, B; Papaioannou, A; Trichopoulos, D, 1981)
"We have infused [6,7-3H]estrone or [6,7-3H]estradiol and [4-14C]estriol into seven women who had had breast cancer and into five normal postmenopausal women."	3.66	Estriol production rates and breast cancer. ( Longcope, C; Pratt, JH, 1978)
"A study designed to test the hypothesis that daughters of breast cancer patients would have "less favorable" estriol proportions than would a group of otherwise similar controls is reported."	3.66	Estrogen profiles in young women: effect of maternal history of breast cancer. ( Brown, JB; Elinson, L; Morgan, RW; Vakil, DV, 1978)
"Urine samples were analyzed for estrone (E1), estradiol (E2), and Estriol (E3) to test the hypothesis that women diagnosed with benign breast disease (high risk for breast cancer?) will have lower estriol proportions (E3/E1 + E2 + E3) than a comparison control group."	3.66	Benign breast disease: estriol proportions and family history of breast cancer. ( Elinson, L; Morgan, RW; Vakil, DV, 1981)
"Population surveys have demonstrated an inverse relationship between breast cancer incidence rates and the urine "estriol ratio," the concentration of estriol relative to the sum of the concentrations of estrone and estradiol."	3.66	Estrogen profiles of premenopausal women with breast cancer. ( Brown, J; Cole, P; Cramer, D; MacMahon, B; Paffenbarger, R; Yen, S, 1978)
"The daily excretion of estrone, estradiol, and estriol was determined for 22 normal women and 35 women with primary breast cancer."	3.66	Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer. ( Dao, TL; Lonergan, PA; Morreal, CE; Nemoto, T, 1979)
"To study the contribution of adrenal glands to circulating estrogens in woman, the concentrations of estrone (E1), estradiol-17 beta (E2), and estriol (E3) in adrenal and peripheral venous blood were measured by radioimmunoassay and the grandular secretion of estrogens after ACTH stimulation was investigated by analyzing the adrenal vein levels of these steroids in patients with breast cancer who were undergoing a therapeutic adrenal operation."	3.66	Adrenal contribution to circulating estrogens in woman. ( Akamine, Y; Ibayashi, H; Kato, K; Nomura, Y; Wasada, T, 1978)
"The effects of estrone, estradiol, and estriol on MCF-7 human breast cancer are compared."	3.65	Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. ( Bolan, G; Lippman, M; Monaco, ME, 1977)
"The metabolism of estradiol, its production rate and the urinary excretion rate of its metabolites were studied in 5 women patients with breast cancer, 2 of whom were postmenopausal and 3 were ovariectomized, both before and after a period of 7beta,17alpha-dimethyltestosterone (calusterone) therapy."	3.65	7beta,17alpha-Dimethyltestosterone (calusterone)-induced changes in the metabolism, production rate, and excretion of estrogens in women with breast cancer: a possible mechanism of action. ( Fishman, J; Hellman, L, 1976)
"Phase I pharmacokinetic (PK) study assessed circulating estrogens in breast cancer (BC) patients on a non-steroidal aromatase inhibitor (NSAI) with vaginal atrophy using vaginal ultra-low-dose 0."	2.79	Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Moegele, M; Neven, P; Ortmann, O; Prasauskas, V, 2014)
"Mammary fibroadenoma is a disease that affects a large number of women of reproductive age."	2.73	Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial. ( Baracat, EC; Estevão, RA; Logullo, AF; Nazário, AC; Oshima, CT, 2007)
"Our findings do not support reduced breast cancer risk with higher postmenopausal 2:16α-OHE1 overall, although obesity may modify associations with 2-OHE1."	2.49	Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data. ( Cauley, JA; Dallal, CM; Fentiman, IS; Fowke, JH; Krogh, V; Loft, S; Meilahn, EN; Muti, P; Ness, RB; Olsen, A; Overvad, K; Sieri, S; Stone, RA; Taioli, E; Tjønneland, A; Ursin, G; Vogel, VG; Wellejus, A, 2013)
"The intensified treatment of breast cancer improves survival but has a price in terms of side-effects."	2.48	The management of menopausal symptoms in breast cancer survivors: case-based approach. ( de Bock, GH; Lammerink, EA; Mourits, MJ; Schröder, CP, 2012)
" However, little is known about the risk of breast cancer and endometrial cancer after long-term use of different estrogen-progestin combinations."	2.41	[Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer]. ( Magnusson, C; Weiderpass, E, 2001)
"The incidence of breast cancer is discussed with regard to dietary habits, geographic location, and economic status."	2.37	Dietary fat and breast cancer. ( Smith, RE, 1987)
"Development of breast cancer is often preceded by the occurrence of preneoplastic mammary lesions, which may be the result of long-term exposure to estrogens and prolactin."	2.36	Pregnancy and lactation in relation to breast cancer risk. ( Vorherr, H, 1979)
"Investigation of the effects of OCs on neoplasia is not easy; currently 4 investigative methods are used: 1) case reports, 2) disease rate and trends, 3) case-control studies, which are the main source of careful retrospective information, and 4) cohort studies, which compare the incidence of disease in patients exposed to suspected environmental factors, and in those who are not exposed."	2.36	Neoplasia and hormonal contraception. ( Huggins, GR, 1981)
"Inanition and obesity have been shown to alter steroid metabolism but it is not known whether nutritional "microdifferences" (i."	2.35	Hormone profiles in hormone-dependent cancers. ( Bradlow, HL; Fishman, J; Hellman, L; Zumoff, B, 1975)
"Current users had a higher risk of breast cancer than never-users: adjusted OR 2."	1.38	The risk of breast cancer linked to menopausal hormone therapy. ( Bakken, K; Lund, E; Sæther, S, 2012)
"Altogether, 2,171 women with breast cancer were identified."	1.33	Breast cancer risk in postmenopausal women using estrogen-only therapy. ( Lyytinen, H; Pukkala, E; Ylikorkala, O, 2006)
"The finding that breast cancer cells that are resistant to conventional chemotherapeutic agents remain sensitive to 2-substituted oestrogen sulphamates offers considerable potential for the treatment of women with drug-resistant breast cancer."	1.32	Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate. ( Leese, MP; Newman, SP; Potter, BV; Purohit, A; Reed, MJ; Suzuki, RN, 2003)
" The D-ring metabolites did not show such clear biphasic patterns, in most of them the stimulatory effect prevailed at the highest dosage used."	1.32	The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. ( Lippert, C; Mueck, AO; Seeger, H, 2003)
" In the present study, we have compared the pharmacokinetic profiles and metabolism of 2-MeOE2 and its sulphamoylated derivative, 2-methoxyoestradiol-bis-sulphamate (2-MeOE2bisMATE), in adult female rats."	1.32	Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. ( Chander, SK; Ireson, CR; Leese, MP; Newman, SP; Parish, D; Perera, S; Potter, BV; Purohit, A; Reed, MJ; Smith, AC, 2004)
"The ability of breast tumors to synthesize sex steroid hormones is well recognized and their local production is thought to play a role in breast cancer development and growth."	1.31	Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. ( Mady, EA; Ossman, AA; Ramadan, EE, 2000)
"As part of a case-control study of breast cancer in Asian-American women, 12-h overnight urine samples were obtained, and a methodological study was conducted to identify laboratories capable of assaying urinary hormones."	1.30	Reproducibility and validity of radioimmunoassays for urinary hormones and metabolites in pre- and postmenopausal women. ( Adlercreutz, H; Donaldson, JL; Falk, RT; Fears, TR; Fillmore, CM; Gail, MH; Hoover, RN; Kiura, P; Rossi, SC; Stanczyk, F; Vaught, JB; Wahala, K; Ziegler, RG, 1999)
"Fifty-six post-menopausal advanced breast cancer patients entered this study to evaluate the activity of four low exemestane doses in reducing oestrogen levels."	1.29	Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. ( Bajetta, E; Buzzoni, R; Di Bartolomeo, M; Di Leo, A; Laffranchi, A; Mariani, L; Martinetti, A; Noberasco, C; Orefice, S; Zilembo, N, 1995)
"We examined this finding on preeclampsia with particular reference to immunologic mechanisms, but further studies are needed on larger samples."	1.27	Characteristics of first pregnancy in relation to early breast cancer. A case-control study. ( Janerich, DT; Polednak, AP, 1983)
"We report two cases of metastatic breast cancer occurring in two postmenopausal women."	1.27	Two partial remissions induced by an LHRH analogue in two postmenopausal women with metastatic breast cancer. ( Guiochet, N; Keiling, R; Schwartz, L, 1988)
"It is concluded that in the MCF-7 human mammary cancer cell line E3 and E3-3-S stimulate PR very significantly, but it is suggested that E3-3-S acts through the hydrolyzed E3."	1.27	Effect of estriol, estriol-3-sulfate and estriol-17-sulfate on progesterone and estrogen receptors of MCF-7 human breast cancer cells. ( Gelly, C; Pasqualini, JR, 1986)
"Some estriol precursors were less inhibitory of breast cancer development among 23 other estrogens and androgens, progestins and glucocorticoids tested."	1.26	Clinical and experimental aspects of the anti-mammary carinogenic activity of estriol. ( Lemon, HM, 1977)
"Findings disclosed that our breast cancer-affected patient showed a distinctive hormonal pattern characterized by significant elevation throughout the cycle of plasma estrone, estradiol, and prolactin."	1.26	Endocrine profile in a patient with familial breast cancer: a case-control study. ( Fishman, J; Harris, RE; Lynch, HT; Lynch, JF; Maloney, K; Marrero, K, 1979)
"Forty patients with advanced breast cancer have been treated by endocrine therapy."	1.26	Significance of aromatase activity in human breast cancer. ( Forrest, AP; Hawkins, RA; Miller, WR, 1982)
"Women who had had breast cancer were compared to a group of normal controls and were also found to have similar blood production rates for estriol, estrone, and estradiol."	1.26	Relationship between urine and plasma estrogen ratios. ( Longcope, C; Pratt, JH, 1978)
"Breast cancer is the most common cancer among American women, whereas in Japan it ranks third behind gastric and uterine cancers."	1.26	Breast cancer in Japan and United States: epidemiology, hormone receptors, pathology, and survival. ( Yonemoto, RH, 1980)
" Analysis of the dose-response curves shows induction by Oe2 to be 10 times and 50 times greater than Oe3 and Oe4, respectively."	1.26	Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture. ( Bayard, F; Jozan, S; Kreitmann, B, 1981)
"In patients with breast and prostate cancer hormone excretion patterns differ in a similar way from patterns in persons without cancer."	1.24	HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL. ( HOPKINS, CE; MARMORSTON, J; STERN, E; WEINER, JM, 1964)

Research

Studies (213)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Variation in Serum Levels of Follicle Stimulating Hormone (FSH)

Timeframe	Studies, this research(%)	All Research%
pre-1990	150 (70.42)	18.7374
1990's	13 (6.10)	18.2507
2000's	23 (10.80)	29.6817
2010's	24 (11.27)	24.3611
2020's	3 (1.41)	2.80

Authors	Studies
Wiese, TE	1
Polin, LA	1
Palomino, E	1
Brooks, SC	3
Comini, ACM	1
Carvalho, BM	1
Moreira, MJB	1
Reis, PCA	1
Colapietro, L	1
Northern, J	1
Batalini, F	1
Li, B	1
Hao, J	1
Yan, X	1
Kong, M	1
Sauter, ER	1
Hirschberg, AL	2
Sánchez-Rovira, P	2
Presa-Lorite, J	1
Campos-Delgado, M	1
Gil-Gil, M	2
Lidbrink, E	1
Suárez-Almarza, J	1
Nieto-Magro, C	2
Bermejo-De Las Heras, B	1
Michels, KB	1
Binder, N	1
Courant, F	1
Franke, AA	1
Osterhues, A	1
Diller, M	1
Schüler, S	1
Buchholz, S	4
Lattrich, C	1
Treeck, O	1
Ortmann, O	4
Donders, G	3
Neven, P	3
Moegele, M	1
Lintermans, A	2
Bellen, G	3
Prasauskas, V	3
Grob, P	3
Liu, S	1
Ruan, X	1
Schultz, S	1
Neubauer, H	1
Fehm, T	1
Seeger, H	4
Mueck, AO	4
Mögele, M	1
Comhaire, FH	1
Depypere, HT	1
Lundström, E	1
Conner, P	1
Naessén, S	1
Löfgren, L	1
Carlström, K	1
Söderqvist, G	1
Holtorf, K	1
Olson, AC	1
Link, JS	1
Waisman, JR	1
Kupiec, TC	1
Lappano, R	1
Rosano, C	1
De Marco, P	1
De Francesco, EM	1
Pezzi, V	1
Maggiolini, M	1
Biglia, N	1
Peano, E	1
Sgandurra, P	1
Moggio, G	1
Panuccio, E	1
Migliardi, M	1
Ravarino, N	1
Ponzone, R	1
Sismondi, P	1
Vorster, C	1
Joubert, A	1
Dimitrakakis, C	1
Zava, D	1
Marinopoulos, S	1
Tsigginou, A	1
Antsaklis, A	1
Glaser, R	1
Pfeiler, G	1
Glatz, C	1
Königsberg, R	1
Geisendorfer, T	1
Fink-Retter, A	1
Kubista, E	1
Singer, CF	1
Seifert, M	1
Recchia, F	1
Candeloro, G	1
Necozione, S	1
Desideri, G	1
Recchia, CO	1
Piazze, J	1
Rea, S	1
Eliassen, AH	1
Spiegelman, D	1
Xu, X	1
Keefer, LK	1
Veenstra, TD	1
Barbieri, RL	1
Willett, WC	1
Hankinson, SE	1
Ziegler, RG	2
Kunovac Kallak, T	1
Baumgart, J	1
Stavreus Evers, A	1
Sundström Poromaa, I	1
Moby, L	1
Kask, K	1
Norjavaara, E	1
Kushnir, MM	1
Bergquist, J	1
Nilsson, K	1
Sæther, S	1
Bakken, K	1
Lund, E	1
Bukowski, R	1
Chlebowski, RT	1
Thune, I	1
Furberg, AS	1
Hankins, GD	1
Malone, FD	1
D'Alton, ME	1
Dallal, CM	1
Stone, RA	1
Cauley, JA	1
Ness, RB	1
Vogel, VG	1
Fentiman, IS	2
Fowke, JH	1
Krogh, V	1
Loft, S	2
Meilahn, EN	1
Muti, P	1
Olsen, A	2
Overvad, K	2
Sieri, S	1
Tjønneland, A	1
Ursin, G	4
Wellejus, A	2
Taioli, E	1
Lammerink, EA	1
de Bock, GH	1
Schröder, CP	1
Mourits, MJ	1
Mariani, L	2
Gadducci, A	1
Vizza, E	1
Tomao, S	1
Vici, P	1
Siyam, T	1
Yuksel, N	1
Cusack, L	1
Brennan, M	1
Baber, R	1
Boyle, F	1
Yared, E	1
McMillan, TJ	1
Martin, FL	1
Lippert, C	1
Suzuki, RN	1
Newman, SP	2
Purohit, A	2
Leese, MP	2
Potter, BV	2
Reed, MJ	2
JULL, LW	1
SHUCKSMITH, HS	1
BONSER, GM	1
SELLEI, C	1
KOEROES, Z	1
ONO, S	1
LEMON, HM	13
PARSONS, L	1
MOZDEN, PH	1
STERN, E	2
HOPKINS, CE	2
WEINER, JM	1
MARMORSTON, J	2
PERSSON, BH	1
RISHOLM, L	1
UKAI, M	1
PULLINGER, BD	1
HEAD, MA	1
OLINA, A	1
MOURAVIEVA, E	1
MANOUYLOVA, IA	1
SMIRNOVA, N	1
CHAROOUKHOVA, K	1
CROWLEY, LG	3
DEMETRIOU, JA	1
KOTIN, P	1
DONOVAN, AJ	1
KUSHINSKY, S	1
MYERS, SM	1
Ireson, CR	1
Chander, SK	1
Perera, S	1
Parish, D	1
Smith, AC	1
Mizunuma, H	1
Dalessandri, KM	1
Firestone, GL	1
Fitch, MD	1
Bradlow, HL	6
Bjeldanes, LF	1
Lagiou, P	1
Samoli, E	1
Lagiou, A	1
Hsieh, CC	1
Adami, HO	1
Trichopoulos, D	5
Tjonneland, A	1
Thomsen, BL	1
Pasqualini, JR	5
Wallwiener, D	1
Kraemer, E	1
Murase, JE	1
Wu, JJ	1
Weinstein, GD	1
Lyytinen, H	1
Pukkala, E	1
Ylikorkala, O	1
Estevão, RA	2
Nazário, AC	2
Baracat, EC	2
Logullo, AF	1
Oshima, CT	1
Qin, F	1
Zhao, YY	1
Sawyer, MB	1
Li, XF	1
Jacobson, HI	1
Lemanski, N	1
Narendran, A	1
Agarwal, A	1
Bennett, JA	1
Andersen, TT	1
Hellman, L	6
Fishman, J	13
Zumoff, B	5
Cassouto, J	1
Gallagher, TF	3
Polednak, AP	1
Janerich, DT	1
Raju, U	2
Blaustein, A	1
Levitz, M	2
Yonemoto, RH	1
Castagnetta, L	1
D'Agostino, C	1
Lo Casto, M	1
Traina, A	1
Leake, RE	1
Molinatti, GM	1
Limone, P	1
Mason, RC	1
Miller, WR	2
Hawkins, RA	2
Brown, MS	1
Forrest, AP	3
Gerasimovich, GI	1
Mikhniuk, DM	1
Duda, IV	1
Katzenellenbogen, BS	1
Bergink, EW	2
Kloosterboer, HJ	1
van der Vies, J	1
Singhakowinta, A	1
Jozan, S	1
Kreitmann, B	1
Bayard, F	1
Fukushima, DK	2
O'Connor, J	3
Rosenfeld, RS	2
Graepel, GJ	1
Elston, R	1
Lynch, H	1
MacMahon, B	11
Brown, J	4
Brown, JB	9
Garas, J	1
Papaioannou, A	1
Utian, WH	1
London, RS	1
Sundaram, GS	1
Schultz, M	1
Nair, PP	1
Goldstein, PJ	1
Huggins, GR	2
El'tsina, NV	1
Zaki, K	1
El-Kharadly, M	1
El-Faras, A	1
Nour, H	1
Kamel, NI	1
Cole, P	10
Andersen, AP	1
Dewaard, F	1
Kauraniemi, T	1
Ravhinar, B	1
Stormby, N	1
Westlund, K	1
Bagli, NP	2
Shah, PN	2
Mistry, SS	1
Vakil, DV	2
Morgan, RW	4
Elinson, L	2
Strobl, JS	1
Monaco, ME	2
Lippman, ME	1
Zilembo, N	1
Noberasco, C	1
Bajetta, E	1
Martinetti, A	1
Orefice, S	1
Buzzoni, R	1
Di Bartolomeo, M	1
Di Leo, A	1
Laffranchi, A	1
Key, TJ	1
Wang, DY	2
Hermon, C	1
Allen, DS	1
Moore, JW	1
Bulbrook, RD	3
Pike, MC	4
London, S	2
Stanczyk, FZ	3
Gentzschein, E	3
Paganini-Hill, A	1
Ross, RK	1
Rodriguez-Sierra, JF	1
Gupta, M	1
McDougal, A	1
Safe, S	1
Falk, RT	1
Gail, MH	1
Fears, TR	1
Rossi, SC	1
Stanczyk, F	1
Adlercreutz, H	1
Kiura, P	1
Wahala, K	1
Donaldson, JL	1
Vaught, JB	1
Fillmore, CM	1
Hoover, RN	1
Singhal, H	1
Guo, L	1
Mittelman, A	1
Tiwari, RK	1
Magnusson, C	1
Weiderpass, E	1
Wilson, M	1
Henderson, BE	2
Kolonel, LN	1
Monroe, K	1
Lee, HP	1
Seow, A	1
Yu, MC	1
Mady, EA	1
Ramadan, EE	1
Ossman, AA	1
Yang, D	1
Tseng, CC	1
Bernstein, L	1
Calabresi, E	1
De Giuli, G	1
Becciolini, A	1
Giannotti, P	1
Lombardi, G	1
Serio, M	1
Maeyama, M	1
Mori, N	1
Miyakawa, I	1
Higashi, S	1
Deshpande, N	2
Carson, P	2
Horner, J	2
Uyttenbroeck, F	1
Sakai, F	1
Saez, S	1
Yamamoto, KR	1
Alberts, BM	1
Wasada, T	1
Akamine, Y	1
Kato, K	1
Ibayashi, H	1
Nomura, Y	1
Kannengiesser, U	1
Völker, W	1
Majewski, A	1
Morreal, CE	4
Dao, TL	6
Nemoto, T	2
Lonergan, PA	1
Kirschner, MA	1
Vorherr, H	2
Messer, RH	1
Lipsett, MB	2
Giuntoli, RL	1
Lynch, HT	3
Harris, RE	1
Lynch, JF	2
Marrero, K	1
Maloney, K	2
Follingstad, AH	1
Cramer, D	1
Yen, S	1
Paffenbarger, R	1
Fukushima, D	1
Guirgis, H	1
Longcope, C	2
Pratt, JH	2
Saracci, R	1
Repetto, F	1
Sklarew, RJ	1
Post, J	1
Thijssen, JH	5
Poortman, J	2
Schwarz, F	2
de Waard, F	3
Lippman, M	1
Bolan, G	1
Gross, J	1
Modan, B	1
Bertini, B	1
Spira, O	1
Vestergaard, P	1
Donegan, WL	1
Casagrande, JT	1
Gerkins, V	1
Swain, MC	1
Hayward, JL	1
Kumaoka, S	1
Takatani, O	1
Abe, O	1
Utsunomiya, J	1
Tominaga, T	2
Tei, N	2
Kitamura, M	2
Taguchi, T	2
Kudo, Y	1
Azuma, Y	1
Tsygan, VM	1
Russu, ID	1
Skul'skaia, SF	1
Jones, AL	1
MacNeill, F	1
Jacobs, S	1
Lonning, PE	1
Dowsett, M	1
Powles, TJ	1
Blankenstein, MA	1
Seshadri, R	2
Bagli-Vania, ND	1
Suraiya, JN	1
Sheth, NA	1
Gelly, C	4
Nguyen, BL	2
Schwartz, L	1
Guiochet, N	1
Keiling, R	1
Hershcopf, R	1
Martucci, C	1
Rochefort, H	1
Capony, F	1
Garcia, M	1
Vignon, F	1
Smith, RE	1
Lecerf, F	2
Giambiagi, N	1
Mayrand, C	1
Hershcopf, RJ	1
Eller, J	1
Aoki, K	2
Lin, TM	2
Woo, N	1
Argüelles, AE	1
Poggi, UL	1
Saborida, C	1
Hoffman, C	1
Chekherdemian, M	1
Blanchard, O	1
Adams, JB	2
Wong, MS	1
Smith, OW	1
Smith, GV	1
Schubert, K	2
Frankenberg, G	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multi-Centre Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aro[NCT02413008]	Phase 2	61 participants (Actual)	Interventional	2015-10-16	Completed
Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study[NCT01862861]		69 participants (Actual)	Observational	2012-11-30	Completed
Prospective, Open-label, Multicenter, Multinational, Randomized Trial to Investigate the Non-inferiority of Treatment With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol in a Panel of Post-menopausal Women Suffering From the Symptoms[NCT03044652]	Phase 4	172 participants (Actual)	Interventional	2016-11-30	Completed
Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.[NCT05585476]		98 participants (Anticipated)	Interventional	2022-12-31	Not yet recruiting
Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio in Premenopausal Mexican Women With Risk of Breast Cancer[NCT02525159]	Phase 3	60 participants (Actual)	Interventional	2006-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change from Baseline (mean screening-baseline) to Week 12 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation) (NCT02413008)
Timeframe: from baseline to 12 weeks of treatment

Change in Pruritus or Itching From Baseline to Week 3 and Week 12

Intervention	mIU/ml (Median)
0.005% Estriol Vaginal Gel	-2.8
Placebo Vaginal Gel	1.4

"Change in pruritus or itching from baseline to week 3 and week 12~Each symptom will be scored in a numeric scale from 0 to 3, as shown below:~0 Absence. The symptom is not present~The symptom is of mild intensity, without interfering in the patient's activity~The symptom is of moderate intensity, causing obvious discomfort to the patient~The symptom is stated as very irritating and severe in intensity" (NCT02413008)
Timeframe: Change from baseline to week 3 and week 12

Changes in Dryness of the Mucosa

Intervention	units on a scale (Median)
	Changes between baseline and week 3	Changes between baseline and week 12
0.005% Estriol Vaginal Gel	0.0	0.0
Placebo Vaginal Gel	0.0	0.0

"It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:~0 Absence. The sign is not present.~The sign is present and is considered a mild alteration~The sign is present and is considered a moderate alteration~The sign is present and is considered a severe alteration" (NCT02413008)
Timeframe: week 3 and week 12 vs baseline

Changes in Dyspareunia

Intervention	score on a scale (Median)
	Changes between baseline and week 3	Changes between baseline and week 12
0.005% Estriol Vaginal Gel	2.0	2.0
Placebo Vaginal Gel	1.0	1.0

"Changes in dyspareunia from baseline to week 3 and week 12 Each symptom will be scored in a numeric scale from 0 to 3, as shown 0 Absence. The symptom is not present~The symptom is of mild intensity, without interfering in the patient's activity~The symptom is of moderate intensity, causing obvious discomfort to the patient~The symptom is stated as very irritating and severe in intensity" (NCT02413008)
Timeframe: week 3 and week 12 vs baseline

Changes in Fragility of the Mucosa [Time Frame: Week 3 and Week 12 vs Baseline]

Intervention	score on a scale (Median)
	Change between baseline and week 3	Change between baseline and week 12
0.005% Estriol Vaginal Gel	1.0	2.0
Placebo Vaginal Gel	1.0	1.0

Changes in Total Score of Signs of Vaginal Atrophy Between Week 3 and Week 12 to Baseline

Intervention	score on a scale (Median)
	Changes from baseline to week 3	Changes from baseline to week 12
0.005% Estriol Vaginal Gel	1.0	1.5
Placebo Vaginal Gel	0.0	0.5

"The signs evaluated Will be the following: vaginal mucosa with flattening of folds or thinning, dryness of the mucosa and Fragility of the mucosa.~It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:~0 Absence. The sign is not present.~The sign is present and is considered a mild alteration~The sign is present and is considered a moderate alteration~The sign is present and is considered a severe alteration A Total Signs Score will be calculated by summing the intensities of all the three signs of vaginal atrophy in a certain time point, thus ranging between 0 and 9." (NCT02413008)
Timeframe: week 3 and week 12 vs baseline

Changes in Total Score of Symptoms of Vaginal Atrophy

Intervention	score on a scale (Median)
	Change between baseline and week 3	Change between baseline and week 12
0.005% Estriol Vaginal Gel	4.0	5.0
Placebo Vaginal Gel	1.0	1.0

"Changes in Symptoms of vaginal atrophy (vaginal dryness, dyspareunia and pruritus) at week 3 and week 12 vs baseline.~Each symptom will be scored in a numeric scale from 0 to 3, as shown below:~0 Absence. The symptom is not present~The symptom is of mild intensity, without interfering in the patient's activity~The symptom is of moderate intensity, causing obvious discomfort to the patient~The symptom is stated as very irritating and severe in intensity A Global Symptoms Score will be calculated by summing the intensities of all the three symptoms of vaginal atrophy in a certain time point, thus ranging between 0 and 9." (NCT02413008)
Timeframe: week 3 and week 12 vs baseline

Changes in Vaginal Dryness

Intervention	score on a scale (Median)
	Change between baseline and week 3	Change between baseline and week 12
0.005% Estriol Vaginal Gel	3.0	4.5
Placebo Vaginal Gel	1.0	2.0

"Change in vaginal dryness puntuation score from baseline to w3 and w12~Each symptom will be scored in a numeric scale from 0 to 3, as shown below:~0 Absence. The symptom is not present~The symptom is of mild intensity, without interfering in the patient's activity~The symptom is of moderate intensity, causing obvious discomfort to the patient~The symptom is stated as very irritating and severe in intensity" (NCT02413008)
Timeframe: week 3 and week 12 vs baseline

Changes in Vaginal Maturation Value

Intervention	units on a scale (Median)
	Change between baseline and week 3	Change between baseline and week 12
0.005% Estriol Vaginal Gel	1.0	2.0
Placebo Vaginal Gel	1.0	1.0

"Vaginal cytology sample to evaluate the vaginal Maturation Value. For the cytologic evaluation, the number of parabasal, intermediate and superficial cells will be calculated in duplicate on 100 consecutive cells of vaginal cytology. The average of the two percentages obtained for each cell type will be calculated, which will serve to determine the maturation value (MV) based on the following formula:~0.2 x (% parabasal) + 0.6 x (% intermediate) + 1.0 x (% superficial)." (NCT02413008)
Timeframe: week 3 and week 12 vs baseline

Changes in Vaginal Mucosa With Flattening of Folds or Thinning

Intervention	% of cells (Median)
	Change between baseline and week 3	Change between baseline and week 12
0.005% Estriol Vaginal Gel	-62.0	-37.2
Placebo Vaginal Gel	-0.6	-1.0

Changes in Vaginal pH Between Baseline and Week 3 and Week 12

Intervention	score on a scale (Median)
	Change between baseline and week 3	Change between baseline and week 12
0.005% Estriol Vaginal Gel	1.0	1.0
Placebo Vaginal Gel	0.0	0.0

Measurement of vaginal pH on the vaginal secretion using a reactive strip and compare pH value between baseline and the diferent timepoints (NCT02413008)
Timeframe: week 3 and week 12 vs baseline

Variation in Plasma Levels of Estradiol

Intervention	units on a scale (Mean)
	Change from baseline to Week 3	Change from baseline to Week 12
0.005% Estriol Vaginal Gel	2.0	1.3
Placebo Vaginal Gel	0.5	0.5

Change in plasma levels of estradiol at weeks 1, 3, 8 and 12 compared to baseline. (NCT02413008)
Timeframe: Change from baseline to week 1, week 3, week 8 and week 12

Variation in Plasma Levels of Estriol

Intervention	pg/mL (Median)
	Change between baseline and week 1	Change between baseline and week 3	Change between baseline and week 8	Change between baseline and week 12
0.005% Estriol Vaginal Gel	0.0	0.0	0.0	0.0
Placebo Vaginal Gel	0.0	0.0	0.0	0.0

Change in plasma levels of estriol at weeks 1, 3, 8 and 12 compared to baseline (NCT02413008)
Timeframe: Change from baseline to week 1, week 3, week 8 and week 12

Variation in Plasma Levels of Estrona

Intervention	pg/mL (Median)
	Change between baseline and week 1	Change between baseline and week 3	Change between baseline and week 8	Change between baseline and week 12
0.005% Estriol Vaginal Gel	-1.7	0.0	0.0	0.0
Placebo Vaginal Gel	0.0	0.0	0.0	0.0

Change in plasma levels of estrona at weeks 1, 3, 8 and 12 compared to baseline. (NCT02413008)
Timeframe: Change from baseline to week 1, week 3, week 8 and week 12

Variation in Serum Levels of FSH at Week 1, Week 3 and Week 8

Intervention	pg/mL (Median)
	Change from baseline to week 1	Change between baseline and week 3	change from baseline to week 8	Change from baseline to week 12
0.005% Estriol Vaginal Gel	0.0	0.0	0.0	0.0
Placebo Vaginal Gel	0.0	0.0	0.0	0.0

Change from Baseline (mean screening-baseline) to Week 1, Week 3 and Week 8 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability ( screening-baseline variation) (NCT02413008)
Timeframe: Change from baseline to week 1, week 3 and week 8

Variation in Serum Levels of Luteinizing Hormone (LH)

Intervention	mIU/ml (Mean)
	change from baseline to week 1	change from baseline to week 3	change from baseline to week 8
0.005% Estriol Vaginal Gel	-4.8	-4.2	-2.6
Placebo Vaginal Gel	4.2	-0.9	5.2

Change from (mean screening-baseline) in plasma levels of LH to Week 1, Week 3, Week 8 and Week 12 in Serum Levels of LH compare to natural physiological variability ( screening-baseline variation) (NCT02413008)
Timeframe: Change from baseline to week 1, week 3, week 8 and week 12

Intervention	mIU/ml (Median)
	change from LH baseline to week 1	change from LH baseline to week 3	change from LH baseline to week 8	change from LH baseline to week 12
0.005% Estriol Vaginal Gel	-0.6	-0.5	-0.3	-0.8
Placebo Vaginal Gel	0.2	0.3	-1.3	1.3

Article	Year
Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis. Clinical breast cancer, 2023, Volume: 23, Issue:8 Topics: Atrophy; Breast Neoplasms; Cancer Survivors; Estradiol; Estriol; Estrogens; Female; Humans; Neoplasm	2023
Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part I. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:3 Topics: Breast Neoplasms; Cardiovascular Diseases; Dietary Supplements; Dyspareunia; Estradiol; Estriol; Est	2015
The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Postgraduate medicine, 2009, Volume: 121, Issue:1 Topics: Breast Neoplasms; Cardiovascular Diseases; Estradiol; Estradiol Congeners; Estriol; Estrogen Replace	2009
Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data. The International journal of biological markers, 2013, Apr-23, Volume: 28, Issue:1 Topics: Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Estriol; Estro	2013
The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas, 2012, Volume: 73, Issue:3 Topics: Acupuncture Therapy; Breast Neoplasms; Estriol; Estrogen Replacement Therapy; Female; Hot Flashes; H	2012
[Treatment of osteoporosis with estrogen]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Bone Density; Breast Neoplasms; Endometrial Neoplasms; Estriol; Estrogen Replacement Therapy; Estrog	2004
Enzymes involved in the formation and transformation of steroid hormones in the fetal and placental compartments. The Journal of steroid biochemistry and molecular biology, 2005, Volume: 97, Issue:5 Topics: Androgens; Breast Neoplasms; Cholesterol; Estriol; Estrogens; Female; Fetus; Glucocorticoids; Gonada	2005
Breast cancer: are estrogen metabolites carcinogenic? Climacteric : the journal of the International Menopause Society, 2007, Volume: 10 Suppl 2 Topics: Administration, Cutaneous; Animals; Breast Neoplasms; Carcinogens; Estradiol; Estriol; Estrogen Repl	2007
[Hormones and breast cancer. Current views]. Minerva medica, 1982, Apr-21, Volume: 73, Issue:17 Topics: Androstenedione; Animals; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans;	1982
Steroid hormones in breast cancer. Special topics in endocrinology and metabolism, 1982, Volume: 4 Topics: Adult; Androgens; Breast Neoplasms; Cytoplasm; Drug Therapy; Endocrine Glands; Estradiol; Estriol; E	1982
Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta endocrinologica. Supplementum, 1980, Volume: 233 Topics: Adolescent; Adult; Aged; Animals; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female;	1980
The place of oestriol therapy after menopause. Acta endocrinologica. Supplementum, 1980, Volume: 233 Topics: Aged; Breast Neoplasms; Costs and Cost Analysis; Estriol; Female; Humans; Menopause; Mental Disorder	1980
Oestriol receptor interactions: their biological importance and therapeutic implications. Acta endocrinologica. Supplementum, 1980, Volume: 233 Topics: Animals; Binding, Competitive; Breast Neoplasms; Castration; Cells, Cultured; Epimestrol; Estradiol;	1980
Neoplasia and hormonal contraception. Clinical obstetrics and gynecology, 1981, Volume: 24, Issue:3 Topics: Animals; Breast Diseases; Breast Neoplasms; Choriocarcinoma; Contraceptives, Oral; Contraceptives, O	1981
[Treatment of malignant breast tumors containing estrogen receptors]. Voprosy onkologii, 1982, Volume: 28, Issue:4 Topics: Animals; Breast Neoplasms; Carcinoma; Cell Line; Cells, Cultured; Cytosol; Drug Resistance; Drug The	1982
Hormonal profiles in women with breast cancer. Obstetrics and gynecology clinics of North America, 1994, Volume: 21, Issue:4 Topics: Adolescent; Adult; Aged; Androgens; Animals; Anovulation; Breast Neoplasms; Child; Estradiol; Estrio	1994
[Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer]. Lakartidningen, 2001, Jan-31, Volume: 98, Issue:5 Topics: Aged; Breast Neoplasms; Case-Control Studies; Climacteric; Endometrial Neoplasms; Estriol; Estrogen	2001
Steroid receptors: elements for modulation of eukaryotic transcription. Annual review of biochemistry, 1976, Volume: 45 Topics: Animals; Bacillus subtilis; Binding Sites; Breast Neoplasms; Cell Line; Cell Nucleus; Chromatin; Col	1976
The role of hormones in the etiology of human breast cancer. Cancer, 1977, Volume: 39, Issue:6 Suppl Topics: 17-Ketosteroids; Androgens; Androsterone; Breast Neoplasms; Contraceptives, Oral, Hormonal; Estradio	1977
Breast cancer: potentially predisposing and protecting factors. Role of pregnancy, lactation, and endocrine status. American journal of obstetrics and gynecology, 1978, Feb-01, Volume: 130, Issue:3 Topics: Adult; Age Factors; Aged; Animals; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female;	1978
Interaction of drugs, hormones, and nutrition in the causes of cancer. Cancer, 1979, Volume: 43, Issue:5 Suppl Topics: Anovulation; Breast Neoplasms; Estradiol Congeners; Estriol; Estrogens; Female; Hormones; Humans; Li	1979
Oral contraceptives and neoplasia. Fertility and sterility, 1979, Volume: 32, Issue:1 Topics: Adolescent; Adult; Breast Neoplasms; Choriocarcinoma; Chronic Disease; Contraceptives, Oral; Contrac	1979
Metabolism of estrogens in breast cancer. Biochimica et biophysica acta, 1979, Dec-19, Volume: 560, Issue:4 Topics: Adrenalectomy; Breast Neoplasms; Castration; Estriol; Estrogens; Female; Humans; Neoplasms, Hormone-	1979
Pregnancy and lactation in relation to breast cancer risk. Seminars in perinatology, 1979, Volume: 3, Issue:3 Topics: Adolescent; Adult; Age Factors; Breast; Breast Neoplasms; DNA; Estriol; Estrogens; Female; Humans; L	1979
Post-menopausal estrogen production, with special reference to patients with mammary carcinoma. Frontiers of hormone research, 1975, Volume: 3 Topics: Age Factors; Aged; Androgens; Androstenedione; Binding, Competitive; Body Weight; Breast Neoplasms;	1975
The metabolism of steroid hormones in breast cancer: a reappraisal. Current topics in molecular endocrinology, 1976, Volume: 4 Topics: Androgens; Androsterone; Breast Neoplasms; Cytochrome P-450 Enzyme System; Estradiol; Estriol; Estro	1976
Hormone profiles in hormone-dependent cancers. Cancer research, 1975, Volume: 35, Issue:11 Pt. 2 Topics: Adrenalectomy; Adult; Age Factors; Androgens; Androsterone; Breast Neoplasms; China; Epidemiologic M	1975
16 alpha-hydroxylation of estradiol: a possible risk marker for breast cancer. Annals of the New York Academy of Sciences, 1986, Volume: 464 Topics: Age Factors; Animals; Breast; Breast Neoplasms; Dihydrotestosterone; Estradiol; Estriol; Female; Hap	1986
The 52K estrogen-regulated protein secreted by breast cancer cells and its clinical potential. Annals of the New York Academy of Sciences, 1986, Volume: 464 Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Division; Cell Line; Cells, Cultured; Diethylstilbest	1986
Dietary fat and breast cancer. Cancer detection and prevention, 1987, Volume: 10, Issue:3-4 Topics: Breast Neoplasms; Dietary Fats; Estradiol; Estriol; Estrone; Feeding Behavior; Female; Humans; Lipid	1987
Competition between steroids for hormonal receptor. National Cancer Institute monograph, 1971, Volume: 34 Topics: Animals; Antineoplastic Agents; Body Fluids; Breast Neoplasms; Castration; Dehydroepiandrosterone; E	1971
Endocrine influences on human mammary cancer formation. A critique. Cancer, 1969, Volume: 23, Issue:4 Topics: Adrenocorticotropic Hormone; Androgens; Androsterone; Animals; Binding Sites; Breast Diseases; Breas	1969
Endocrine, genetic and viral factors in the etiology of breast cancer. Proceedings of the Royal Society of Medicine, 1972, Volume: 65, Issue:7 Topics: Adolescent; Adult; Androsterone; Animals; Breast Diseases; Breast Neoplasms; Castration; Endocrine S	1972
Some hormonal and genetic aspects of human breast cancer--a review. Indian journal of cancer, 1973, Volume: 10, Issue:1 Topics: 17-Hydroxycorticosteroids; Adrenalectomy; Adult; Androgens; Breast Neoplasms; Chromosome Aberrations	1973
The ovarian etiology of human breast cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1972, Volume: 39 Topics: Adolescent; Adult; Age Factors; Aged; Asia; Breast Neoplasms; Castration; Child; Climacteric; Estrio	1972
Proceedings: Epidemiology of human breast cancer. The Journal of investigative dermatology, 1974, Volume: 63, Issue:1 Topics: Adolescent; Adult; Aged; Androgens; Boston; Breast Neoplasms; Epidemiologic Methods; Estriol; Estrog	1974
Etiologic factors in cancer of the breast in humans. Surgery, gynecology & obstetrics, 1974, Volume: 138, Issue:2 Topics: Adrenal Cortex Hormones; Adult; Age Factors; Androgens; Animals; Breast Neoplasms; Contraceptives, O	1974
The pill and the breast. New York state journal of medicine, 1970, Dec-01, Volume: 70, Issue:23 Topics: Adult; Age Factors; Breast; Breast Feeding; Breast Neoplasms; Castration; Child; Contraceptives, Ora	1970
[Steroid changes in malignant mastopathy]. Studii si cercetari de endocrinologie, 1970, Volume: 21, Issue:5 Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Glands; Animals; Breast Neoplasms; Estradiol; Es	1970
[Climacteric in the woman]. Medizinische Klinik, 1971, Sep-17, Volume: 66, Issue:38 Topics: Breast Neoplasms; Climacteric; Estradiol; Estriol; Estrogens; Female; Genital Neoplasms, Female; Gen	1971

Article	Year
Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-contr Menopause (New York, N.Y.), 2020, Volume: 27, Issue:5 Topics: Administration, Intravaginal; Aromatase Inhibitors; Atrophy; Breast Neoplasms; Estriol; Estrogens; F	2020
A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aroma The oncologist, 2020, Volume: 25, Issue:12 Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estriol; Estrogens; Female; Humans; Middle Aged;	2020
Urinary excretion of sex steroid hormone metabolites after consumption of cow milk: a randomized crossover intervention trial. The American journal of clinical nutrition, 2019, 02-01, Volume: 109, Issue:2 Topics: Aged; Androgens; Animals; Breast Neoplasms; Cattle; Cross-Over Studies; Diet; Dietary Fats; Estradio	2019
Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast cancer research and treatment, 2014, Volume: 145, Issue:2 Topics: Administration, Intravaginal; Aromatase Inhibitors; Atrophy; Breast Neoplasms; Estradiol; Estriol; F	2014
Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric : the journal of the International Menopause Society, 2011, Volume: 14, Issue:3 Topics: Administration, Intravaginal; Aromatase Inhibitors; Breast Neoplasms; Chromatography, Gas; Drug Moni	2011
Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutrition and cancer, 2004, Volume: 50, Issue:2 Topics: Aged; Breast Neoplasms; Dietary Supplements; Estradiol; Estriol; Female; Hormones; Humans; Hydrocort	2004
Effect of oral contraceptive with and without associated estriol on ultrasound measurements of breast fibroadenoma: randomized clinical trial. Sao Paulo medical journal = Revista paulista de medicina, 2007, Sep-06, Volume: 125, Issue:5 Topics: Adult; Biopsy; Breast Neoplasms; Contraceptives, Oral, Combined; Double-Blind Method; Estriol; Ethin	2007
Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial. Sao Paulo medical journal = Revista paulista de medicina, 2007, Nov-01, Volume: 125, Issue:6 Topics: Adult; Biopsy; Breast Neoplasms; Cell Proliferation; Contraceptives, Oral, Combined; Double-Blind Me	2007
Endocrine parameters and alpha-tocopherol therapy of patients with mammary dysplasia. Cancer research, 1981, Volume: 41, Issue:9 Pt 2 Topics: Adolescent; Adult; Breast Diseases; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method;	1981

Article	Year
Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study. Journal of medicinal chemistry, 1997, Oct-24, Volume: 40, Issue:22 Topics: Breast Neoplasms; Estradiol; Estrogens; Humans; Models, Molecular; Receptors, Estrogen; Structure-Ac	1997
A-FABP and oestrogens are independently involved in the development of breast cancer. Adipocyte, 2019, Volume: 8, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Comorbidity; Double-Blind Method; Estradiol; Estri	2019
Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines. Maturitas, 2014, Volume: 77, Issue:4 Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin A2; Cyclin B1; Estriol; Estrogen Rece	2014
Oestetrol stimulates proliferation and oestrogen receptor expression in breast cancer cell lines: comparison of four oestrogens. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2015, Volume: 20, Issue:1 Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estetrol; Estradiol; Estriol; Estrogen Recep	2015
Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:2 Topics: Administration, Intravaginal; Aromatase Inhibitors; Atrophy; Breast Neoplasms; Combined Modality The	2015
Estrone - a partial estradiol antagonist in the normal breast. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2015, Volume: 31, Issue:9 Topics: Aged; Breast; Breast Density; Breast Neoplasms; Contraceptives, Oral; Drug Combinations; Estradiol;	2015
Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015, Volume: 34, Issue:10 Topics: Administration, Intravaginal; Adult; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Candida; Ca	2015
Breast cancer patients unknowingly dosing themselves with estrogen by using topical moisturizers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26 Topics: Administration, Cutaneous; Breast Neoplasms; Chromatography, High Pressure Liquid; Emollients; Estra	2009
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Molecular and cellular endocrinology, 2010, May-14, Volume: 320, Issue:1-2 Topics: Binding Sites; Binding, Competitive; Biological Assay; Breast Neoplasms; Cell Line, Tumor; Cell Prol	2010
Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2010, Volume: 26, Issue:6 Topics: Acrylic Resins; Administration, Intravaginal; Atrophy; Breast Neoplasms; Estradiol; Estriol; Estroge	2010
In vitro effects of 2-methoxyestradiol-bis-sulphamate on cell growth, morphology and cell cycle dynamics in the MCF-7 breast adenocarcinoma cell line. Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al, 2010, Volume: 34, Issue:2 Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Shape; Estriol; Female; Hum	2010
Low salivary testosterone levels in patients with breast cancer. BMC cancer, 2010, Oct-11, Volume: 10 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estriol; Estron	2010
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy. Anticancer research, 2011, Volume: 31, Issue:2 Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; C	2011
Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer research, 2012, Feb-01, Volume: 72, Issue:3 Topics: Adult; Breast Neoplasms; Case-Control Studies; Cell Transformation, Neoplastic; Chromatography, Liqu	2012
Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients. Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:5 Topics: Administration, Intravaginal; Aged; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cross-Section	2012
The risk of breast cancer linked to menopausal hormone therapy. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2012, Jun-12, Volume: 132, Issue:11 Topics: Breast Neoplasms; Case-Control Studies; Drug Therapy, Combination; Estradiol; Estriol; Estrogen Rece	2012
Birth weight, breast cancer and the potential mediating hormonal environment. PloS one, 2012, Volume: 7, Issue:7 Topics: alpha-Fetoproteins; Birth Weight; Breast Neoplasms; Cohort Studies; Estriol; Female; Hormones; Human	2012
Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2013, Volume: 29, Issue:1 Topics: Administration, Intravaginal; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Atrophy; Breast	2013
Beliefs about bioidentical hormone therapy: a cross-sectional survey of pharmacists. Maturitas, 2013, Volume: 74, Issue:2 Topics: Adult; Alberta; Attitude of Health Personnel; Breast Neoplasms; Cardiovascular Diseases; Cross-Secti	2013
Menopausal symptoms in breast cancer survivors: management update. The British journal of general practice : the journal of the Royal College of General Practitioners, 2013, Volume: 63, Issue:606 Topics: Aged; Antineoplastic Agents; Anxiety; Breast Neoplasms; Clinical Trials as Topic; Depression; Estrio	2013
Genotoxic effects of oestrogens in breast cells detected by the micronucleus assay and the Comet assay. Mutagenesis, 2002, Volume: 17, Issue:4 Topics: Adult; Breast; Breast Neoplasms; Carcinoma; Cell Survival; Cells, Cultured; Comet Assay; Dose-Respon	2002
The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life sciences, 2003, Jan-10, Volume: 72, Issue:8 Topics: Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estriol; Estrone; Fema	2003
Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate. The Journal of steroid biochemistry and molecular biology, 2003, Volume: 84, Issue:2-3 Topics: 2-Methoxyestradiol; Biocompatible Materials; Breast Neoplasms; Cell Cycle; Cell Division; Collagen;	2003
A study of urinary estrogen excretion in relation to breast cancer. The Journal of clinical endocrinology and metabolism, 1963, Volume: 23 Topics: Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Humans; Pregnanediol	1963
MEDICAL TREATMENT OF CANCER OF THE BREAST. Therapia Hungarica (English edition), 1963, Volume: 11 Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adrenalectomy; Antineoplastic Agents; Breast Neoplasms; Es	1963
[STUDIES ON THE EXTRAGONADAL ESTROGENS]. Nihon Naibunpi Gakkai zasshi, 1963, Nov-20, Volume: 39 Topics: Adrenal Cortex Hormones; Adrenalectomy; Adrenocorticotropic Hormone; Animals; Breast Neoplasms; Cast	1963
ABDOMINOVAGINAL POTENTIAL DIFFERENCE IN POSTMENOPAUSAL PATIENTS WITH AND WITHOUT BREAST CANCER. Cancer, 1964, Volume: 17 Topics: Abdominal Wall; Adolescent; Androgens; Breast Neoplasms; Castration; Climacteric; Electrophysiology;	1964
HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL. Science (New York, N.Y.), 1964, Aug-14, Volume: 145, Issue:3633 Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Aged; Androsterone; Breast Neoplasms; Creatine; Creatinine	1964
OOPHORECTOMY AND CORTISONE TREATMENT AS A METHOD OF ELIMINATING OESTROGEN PRODUCTION IN PATIENTS WITH BREAST CANCER. Acta endocrinologica, 1964, Volume: 47 Topics: 17-Hydroxycorticosteroids; Breast Neoplasms; Castration; Cortisone; Estradiol; Estriol; Estrogens; E	1964
STUDIES ON URINARY ESTROGENS IN PATIENTS WITH ADVANCED BREAST CANCER IN REFERENCE TO OOPHORECTOMY AND ADRENALECTOMY. Nagoya journal of medical science, 1964, Volume: 27 Topics: Adrenalectomy; Biomedical Research; Breast Neoplasms; Castration; Estradiol; Estriol; Estrogens; Est	1964
HEPATOMA IN INTACT C3HF MALE AND VIRGIN FEMALE MICE AND AFTER GONADECTOMY ALONE OR SEBSEQUENT TREATMENT WITH OESTROGEN. British journal of cancer, 1964, Volume: 13 Topics: Animals; Body Weight; Breast Neoplasms; Carcinoma, Hepatocellular; Castration; Diet; Estradiol; Estr	1964
THE EXCRETION OF OESTROGENS AND PREGNANEDIOL IN PATIENTS WITH MAMMARY CARCINOMA. Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20 Topics: Breast Neoplasms; Drug Therapy; Estradiol; Estriol; Estrogens; Estrone; Female; Fluids and Secretion	1964
[PECULIARITIES OF HORMONAL DISTURBANCES IN MASTOPATHY]. Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20 Topics: Adrenal Cortex Hormones; Breast Neoplasms; Estriol; Estrogens; Female; Fluids and Secretions; Humans	1964
EXCRETION PATTERNS OF URINARY METABOLITES OF ESTRADIOL-4-C-14 IN POSTMENOPAUSAL WOMEN WITH BENIGN AND MALIGNANT DISEASE OF THE BREAST. Cancer research, 1965, Volume: 25 Topics: Breast; Breast Diseases; Breast Neoplasms; Carbon Isotopes; Estradiol; Estriol; Estrone; Ethinyl Est	1965
II. URINARY EXCRETION OF ESTRONE, ESTRADIOL, AND ESTRIOL BY PATIENTS WITH BREAST CANCER AND BENIGN BREAST DISEASE. American journal of obstetrics and gynecology, 1965, Jun-15, Volume: 92 Topics: Breast Diseases; Breast Neoplasms; Contraceptive Agents, Female; Estradiol; Estriol; Estrogens; Estr	1965
Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. British journal of cancer, 2004, Feb-23, Volume: 90, Issue:4 Topics: 2-Methoxyestradiol; Administration, Oral; Animals; Biological Availability; Breast Neoplasms; Dose-R	2004
Maternal height, pregnancy estriol and birth weight in reference to breast cancer risk in Boston and Shanghai. International journal of cancer, 2005, Nov-10, Volume: 117, Issue:3 Topics: Birth Weight; Body Height; Boston; Breast Neoplasms; China; Estriol; Female; Gestational Age; Humans	2005
Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2005, Volume: 14, Issue:9 Topics: Biomarkers; Breast Neoplasms; Case-Control Studies; Estriol; Female; Hormone Replacement Therapy; Hu	2005
Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas, 2006, Apr-20, Volume: 54, Issue:1 Topics: Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytochromes c;	2006
Estrogen and the skin. Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:6 Topics: Autoimmune Diseases; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrogens, Conjugated (USP); F	2006
Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstetrics and gynecology, 2006, Volume: 108, Issue:6 Topics: Administration, Cutaneous; Administration, Intravaginal; Administration, Oral; Aged; Aged, 80 and ov	2006
Hydrophilic interaction liquid chromatography-tandem mass spectrometry determination of estrogen conjugates in human urine. Analytical chemistry, 2008, May-01, Volume: 80, Issue:9 Topics: Adult; Breast Neoplasms; Chromatography, Liquid; Estradiol; Estriol; Estrogens, Conjugated (USP); Es	2008
Hormones of pregnancy, alpha-feto protein, and reduction of breast cancer risk. Advances in experimental medicine and biology, 2008, Volume: 617 Topics: alpha-Fetoproteins; Animals; Breast Neoplasms; Carcinogens; Carcinoma, Hepatocellular; Cell Prolifer	2008
Studies of estradiol transformation in women with breast cancer. The Journal of clinical endocrinology and metabolism, 1967, Volume: 27, Issue:8 Topics: Aged; Biotransformation; Breast Neoplasms; Chromatography; Estradiol; Estriol; Estrogens; Estrone; F	1967
Characteristics of first pregnancy in relation to early breast cancer. A case-control study. The Journal of reproductive medicine, 1983, Volume: 28, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Estriol; Female; Gestational	1983
Conjugation of androgens and estrogens by human breast tumors in vitro. Steroids, 1980, Volume: 35, Issue:6 Topics: Adult; Aged; Androgens; Androstane-3,17-diol; Androstenedione; Androsterone; Breast Neoplasms; Carci	1980
Breast cancer in Japan and United States: epidemiology, hormone receptors, pathology, and survival. Archives of surgery (Chicago, Ill. : 1960), 1980, Volume: 115, Issue:9 Topics: Adult; Aged; Breast Neoplasms; Dietary Fats; Estriol; Estrogens; Female; Humans; Japan; Middle Aged;	1980
Breast cancer: a comparison of response to endocrine therapy and oestrogen excretion patterns including unusual metabolites. British journal of cancer, 1981, Volume: 44, Issue:5 Topics: Aged; Breast Neoplasms; Diethylstilbestrol; Estriol; Estrogens; Female; Hexestrol; Humans; Middle Ag	1981
Effects of drugs associated with hyperprolactinemia on plasma steroids and on steroid receptors and metabolism in human breast cancer. Breast cancer research and treatment, 1983, Volume: 3, Issue:4 Topics: Aged; Breast Neoplasms; Estriol; Estrone; Female; Hormones; Humans; Methyldopa; Middle Aged; Neoplas	1983
[Estriol and its role in reproductive function]. Akusherstvo i ginekologiia, 1984, Issue:3 Topics: Abortion, Spontaneous; Animals; Breast Neoplasms; Embryo Implantation; Estriol; Female; Fertility; F	1984
Biology and receptor interactions of estriol and estriol derivatives in vitro and in vivo. Journal of steroid biochemistry, 1984, Volume: 20, Issue:4B Topics: Animals; Breast Neoplasms; Cell Line; Endometrium; Estradiol; Estriol; Ethinyl Estradiol; Female; Hu	1984
Oestrogen binding proteins in the female genital tract. Journal of steroid biochemistry, 1984, Volume: 20, Issue:4B Topics: Aged; Binding, Competitive; Breast Neoplasms; Carrier Proteins; Diethylstilbestrol; Estradiol; Estri	1984
Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture. Acta endocrinologica, 1981, Volume: 98, Issue:1 Topics: Breast Neoplasms; Cell Division; Cell Line; Estetrol; Estradiol; Estriol; Estrone; Female; Humans; L	1981
Abnormal estrogen conjugation in women at risk for familial breast cancer at the periovulatory stage of the menstrual cycle. Cancer research, 1983, Volume: 43, Issue:4 Topics: Androgens; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Luteinizing Hor	1983
Socioeconomic status, urine estrogens, and breast cancer risk. Journal of the National Cancer Institute, 1980, Volume: 64, Issue:4 Topics: Adolescent; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Follicular Phase; Huma	1980
Elevated urine estrogen and pregnanediol levels in daughters of breast cancer patients. Journal of the National Cancer Institute, 1981, Volume: 67, Issue:3 Topics: Adolescent; Adult; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Menstru	1981
Significance of aromatase activity in human breast cancer. Cancer research, 1982, Volume: 42, Issue:8 Suppl Topics: Adrenalectomy; Aminoglutethimide; Aromatase; Breast Neoplasms; Estradiol; Estriol; Estrogens; Female	1982
Urinary oestrogens and pregnandiol in breast cancer patients. Endokrinologie, 1982, Volume: 79, Issue:1 Topics: Adult; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Mastectomy; Middle	1982
Cigarette smoking and urinary estrogens. The New England journal of medicine, 1982, Oct-21, Volume: 307, Issue:17 Topics: Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Menopause; Menstruation; M	1982
Urine estrogen profiles in European countries with high or low breast cancer rates. European journal of cancer, 1980, Volume: 16, Issue:12 Topics: Adolescent; Adult; Age Factors; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Europe; Fe	1980
The estriol quotient in fibrocystic disease, a high-risk group for breast cancer. Indian journal of cancer, 1980, Volume: 17, Issue:4 Topics: Adult; Aged; Breast Diseases; Breast Neoplasms; Climacteric; Estriol; Female; Fibrocystic Breast Dis	1980
Benign breast disease: estriol proportions and family history of breast cancer. Cancer detection and prevention, 1981, Volume: 4, Issue:1-4 Topics: Adult; Age Factors; Breast Diseases; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Humans	1981
The role of intracellular equilibria and the effect of antiestrogens on estrogen-receptor dissociation kinetics from perfused cultures of human breast cancer cells. Endocrinology, 1980, Volume: 107, Issue:2 Topics: Binding Sites; Breast Neoplasms; Cell Line; Clomiphene; Estradiol; Estriol; Female; Humans; Kinetics	1980
Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. British journal of cancer, 1995, Volume: 72, Issue:4 Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme I	1995
A prospective study of urinary oestrogen excretion and breast cancer risk. British journal of cancer, 1996, Volume: 73, Issue:12 Topics: Adult; Breast Neoplasms; Case-Control Studies; Estradiol; Estriol; Estrogens; Estrone; Female; Human	1996
A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. Environmental health perspectives, 1997, Volume: 105 Suppl 3 Topics: Breast Neoplasms; Case-Control Studies; Estradiol; Estriol; Estrone; Female; Humans; Hydroxyestrones	1997
Re: ethnic differences in estrogen metabolism in healthy women. Journal of the National Cancer Institute, 1997, Nov-05, Volume: 89, Issue:21 Topics: Adolescent; Adult; Breast; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrogens, Catechol; Fem	1997
Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. The Journal of steroid biochemistry and molecular biology, 1998, Volume: 67, Issue:5-6 Topics: Breast Neoplasms; Cathepsin D; Cell Division; Creatine Kinase; Estradiol; Estriol; Female; Humans; H	1998
Reproducibility and validity of radioimmunoassays for urinary hormones and metabolites in pre- and postmenopausal women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1999, Volume: 8, Issue:6 Topics: Adult; Asian; Bias; Breast Neoplasms; Case-Control Studies; Estradiol; Estriol; Estrone; Female; Gas	1999
Endocrine characteristics of human breast epithelial cells, MCF-10F. Hormone research, 1999, Volume: 52, Issue:4 Topics: 9,10-Dimethyl-1,2-benzanthracene; Aromatase; Aryl Hydrocarbon Hydroxylases; Breast; Breast Neoplasms	1999
Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? Cancer research, 2001, Apr-15, Volume: 61, Issue:8 Topics: Aged; Black People; Breast Neoplasms; China; Cohort Studies; Estradiol; Estriol; Estrogens; Estrone;	2001
Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Disease markers, 2000, Volume: 16, Issue:3-4 Topics: Adult; Aged; Biomarkers; Breast Diseases; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Ca	2000
Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women. Breast cancer research and treatment, 2002, Volume: 72, Issue:2 Topics: Adult; Biomarkers; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Genetic Predisp	2002
Oestrogen profiles of parous and nulliparous women. Lancet (London, England), 1976, Sep-18, Volume: 2, Issue:7986 Topics: Adult; Age Factors; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Follicular Phase; Humans;	1976
Clinical and experimental aspects of the anti-mammary carinogenic activity of estriol. Frontiers of hormone research, 1977, Volume: 5 Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Breast Neoplasms; Estriol; Estrone	1977
7beta,17alpha-Dimethyltestosterone (calusterone)-induced changes in the metabolism, production rate, and excretion of estrogens in women with breast cancer: a possible mechanism of action. The Journal of clinical endocrinology and metabolism, 1976, Volume: 42, Issue:2 Topics: Adult; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Humans; Methyltestosterone; Middle Age	1976
Plasma estrogens and androgens in male breast cancer. Journal of steroid biochemistry, 1976, Volume: 7 Topics: Adult; Aged; Androgens; Androstenedione; Breast Neoplasms; Castration; Dehydroepiandrosterone; Dihyd	1976
Urinary steroid excretion in an oophorectomized and adrenalectomized woman in the second trimester of pregnancy. The Journal of endocrinology, 1975, Volume: 64, Issue:2 Topics: 17-Hydroxycorticosteroids; Adrenalectomy; Adrenocorticotropic Hormone; Breast Neoplasms; Castration;	1975
Proceedings: Uptake of tritiated oestriol by human breast tumours. The Journal of endocrinology, 1975, Volume: 65, Issue:3 Topics: Breast Neoplasms; Estradiol; Estriol; Estrogen Antagonists; Female; Humans; Receptors, Cell Surface	1975
[Personal experience with patients in climacteric and post-climacteric]. Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie, 1975, Volume: 37, Issue:4 Topics: Adolescent; Adult; Age Factors; Aged; Breast Neoplasms; Child; Climacteric; Contraceptives, Oral, Ho	1975
Existence of receptors bound to endogenous estradiol in breast cancers of premenopausal and postmenopausal women. Steroids, 1976, Volume: 27, Issue:1 Topics: Adenocarcinoma; Breast; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Nucleus; Cytosol; Estradiol	1976
Adrenal contribution to circulating estrogens in woman. Endocrinologia japonica, 1978, Volume: 25, Issue:2 Topics: Adrenal Glands; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Aged; Breast Neoplasms; Estradiol	1978
[Estrogen therapy and breast cancer]. Archives of gynecology, 1979, Jul-20, Volume: 228, Issue:1-4 Topics: Breast Neoplasms; Estriol; Estrogens; Estrogens, Conjugated (USP); Female; Humans	1979
Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer. Journal of the National Cancer Institute, 1979, Volume: 63, Issue:5 Topics: Aged; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Humans; Menopause; Middle Aged; Risk	1979
My specialty: oncology. The Nebraska medical journal, 1979, Volume: 64, Issue:8 Topics: Adult; Animals; Breast Neoplasms; Estriol; Female; History of Medicine; Humans; Medical Oncology; Ne	1979
Low urinary estrogen glucuronides in women at risk for familial breast cancer. Science (New York, N.Y.), 1979, Jun-08, Volume: 204, Issue:4397 Topics: Adult; Age Factors; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Menopa	1979
Endocrine profile in a patient with familial breast cancer: a case-control study. Cancer, 1979, Volume: 44, Issue:5 Topics: Adult; Breast Neoplasms; Endocrine Glands; Estradiol; Estriol; Estrone; Female; Follicle Stimulating	1979
Estriol, the forgotten estrogen? JAMA, 1978, Jan-02, Volume: 239, Issue:1 Topics: Breast Neoplasms; Estriol; Female; Humans; Osteoporosis; Risk; United States; United States Food and	1978
Estrogen profiles of premenopausal women with breast cancer. Cancer research, 1978, Volume: 38, Issue:3 Topics: Adult; Breast Neoplasms; Contraceptives, Oral; Estradiol; Estriol; Estrogens; Estrone; Female; Human	1978
Estrogen profiles in young women: effect of maternal history of breast cancer. Journal of the National Cancer Institute, 1978, Volume: 60, Issue:5 Topics: Adolescent; Adult; Breast Neoplasms; Child; Estradiol; Estriol; Estrogens; Estrone; Family Character	1978
Plasma hormone profiles of young women at risk for familial breast cancer. Cancer research, 1978, Volume: 38, Issue:11 Pt 2 Topics: Adult; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Family Characteristics; Female; Fol	1978
Relationship between urine and plasma estrogen ratios. Cancer research, 1978, Volume: 38, Issue:11 Pt 2 Topics: Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Follicular Phase; Humans; Luteal P	1978
Epidemiology of breast cancer. Seminars in oncology, 1978, Volume: 5, Issue:4 Topics: Adult; Age Factors; Aged; Breast Neoplasms; Environment; Epidemiologic Methods; Estriol; Ethnicity;	1978
Steroid metabolism in human breast cancer cell lines. Steroids, 1978, Volume: 32, Issue:5 Topics: Androstenedione; Biotransformation; Breast Neoplasms; Cell Line; Chromatography, Gel; Estriol; Etioc	1978
Estriol production rates and breast cancer. The Journal of clinical endocrinology and metabolism, 1978, Volume: 46, Issue:1 Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Humans; Menopause; Middle Aged	1978
Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer research, 1977, Volume: 37, Issue:6 Topics: Binding, Competitive; Breast Neoplasms; Cell Nucleus; Culture Techniques; Cytoplasm; Drug Interactio	1977
Relationship between steroid excretion patterns and breast cancer incidence in Israeli women of various origins. Journal of the National Cancer Institute, 1977, Volume: 59, Issue:1 Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Aged; Androgens; Breast Neoplasms; Environment; Estriol; E	1977
Breast cancer and pregnancy. Obstetrics and gynecology, 1977, Volume: 50, Issue:2 Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Antineoplastic Agents; Breast Neoplasms; Cast	1977
Comparison of urinary and plasma hormone levels in daughters of breast cancer patients and controls. Journal of the National Cancer Institute, 1977, Volume: 59, Issue:5 Topics: Adolescent; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Follicular Phase; Huma	1977
Breast cancer in Britain and Japan: plasma oestradiol-17beta, oestrone and progesterone,and their urinary metabolites in normal British and Japanese women. European journal of cancer, 1976, Volume: 12, Issue:9 Topics: Adolescent; Adult; Age Factors; Asian People; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estro	1976
Letter: Factors that influence mammary carcinogenesis. The New England journal of medicine, 1975, May-01, Volume: 292, Issue:18 Topics: Adult; Animals; Asian People; Body Height; Body Weight; Breast Neoplasms; Estriol; Female; Humans; R	1975
Editorial: Breast cancer and the discriminant. British medical journal, 1975, Apr-19, Volume: 2, Issue:5963 Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenalectomy; Adult; Breast Neoplasms; Estriol; Female;	1975
Protection of estrogenic hormones by ascorbic acid during chromatography. Steroids, 1975, Volume: 25, Issue:3 Topics: Aged; Ascorbic Acid; Breast Neoplasms; Chromatography, Gas; Chromatography, Thin Layer; Estradiol; E	1975
Urinary excretion of steroids by Japanese women with breast cancer. Gan, 1975, Volume: 66, Issue:3 Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Asian People; Breast Neoplasms; Estradiol; Estrio	1975
Urinary excretion of steroids and response to oophorectomy in premenopausal women with advanced breast cancer. Gan, 1975, Volume: 66, Issue:4 Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Cortex Hormones; Adult; Breast Neoplasms; Castra	1975
[Estrogen excretion and sex chromatin content in the tumor cells of breast cancer patients]. Voprosy onkologii, 1975, Volume: 21, Issue:11 Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Menstruation;	1975
Oestriol in human breast tumors. Journal of steroid biochemistry, 1976, Volume: 7, Issue:1 Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estriol; Female; Humans; Middle Aged	1976
The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:10 Topics: Aged; Aged, 80 and over; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neopla	1992
Uptake and metabolism of estradiol by normal and abnormal breast tissues. Annals of the New York Academy of Sciences, 1990, Volume: 586 Topics: Adult; Breast; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Fibrocystic Breast Disease; Hu	1990
Conversion to estriol in "normal", benign and malignant human breast tissues. Journal of cancer research and clinical oncology, 1990, Volume: 116, Issue:3 Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Breast; Breast Neoplasms; Culture Techniques; Cytochrome	1990
Metabolism and biologic response of estrogen sulfates in hormone-dependent and hormone-independent mammary cancer cell lines. Effect of antiestrogens. Annals of the New York Academy of Sciences, 1990, Volume: 595 Topics: Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Humans; Menstruation; Polyunsaturated Alkamid	1990
Two partial remissions induced by an LHRH analogue in two postmenopausal women with metastatic breast cancer. Cancer, 1988, Dec-15, Volume: 62, Issue:12 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Follicle Stimulating	1988
Biological effects and morphological responses to estriol, estriol-3-sulfate, estriol-17-sulfate and tamoxifen in a tamoxifen-resistant cell line (R-27) derived from MCF-7 human breast cancer cells. European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:12 Topics: Breast Neoplasms; Cell Line; Dose-Response Relationship, Drug; Drug Resistance; Estriol; Humans; Mic	1986
Effect of estriol, estriol-3-sulfate and estriol-17-sulfate on progesterone and estrogen receptors of MCF-7 human breast cancer cells. Journal of steroid biochemistry, 1986, Volume: 24, Issue:1 Topics: Breast Neoplasms; Cell Line; Estriol; Female; Humans; Receptors, Estrogen; Receptors, Progesterone	1986
[Effect of tamoxifen and estrogens on breast cancer cell lines: MCF-7 and R-27, and on the uterus and vagina of fetal and newborn guinea-pigs]. Pathologie-biologie, 1985, Volume: 33, Issue:10 Topics: Animals; Animals, Newborn; Breast Neoplasms; Cell Line; Estradiol; Estriol; Estrogens; Female; Fetus	1985
Biochemical epidemiology of breast cancer. Progress in clinical and biological research, 1986, Volume: 204 Topics: Adult; Age Factors; Aged; Breast Neoplasms; Estradiol; Estriol; Estrogens; Female; Humans; Hydroxyla	1986
Effects of the antiandrogen cyproterone acetate on estradiol production and metabolism in man. Steroids, 1970, Volume: 16, Issue:4 Topics: 17-Hydroxycorticosteroids; Acetates; Aged; Breast Neoplasms; Castration; Estradiol; Estriol; Estrone	1970
Oestrogen profiles of Asian and North American women. Lancet (London, England), 1971, Oct-23, Volume: 2, Issue:7730 Topics: Adolescent; Adult; Age Factors; Asia; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Fema	1971
Estrogen profiles and breast cancer. Lancet (London, England), 1971, Dec-18, Volume: 2, Issue:7738 Topics: Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Pregnancy	1971
Endocrine profiles and breast cancer. Lancet (London, England), 1973, Jan-27, Volume: 1, Issue:7796 Topics: 11-Hydroxycorticosteroids; Adult; Aged; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estriol	1973
Oestriol and prevention of breast cancer. Lancet (London, England), 1973, Mar-10, Volume: 1, Issue:7802 Topics: Adolescent; Adult; Animals; Benz(a)Anthracenes; Breast Neoplasms; Estriol; Female; Humans; Hydroxyla	1973
A correlation between urinary steroid metabolites and pathways of steroidogenesis in human breast-tumour tissue. Lancet (London, England), 1968, Nov-30, Volume: 2, Issue:7579 Topics: 17-Ketosteroids; Adenofibroma; Adrenalectomy; Adult; Aged; Androstanes; Breast Neoplasms; Carcinoma;	1968
Urinary oestrogen profiles and aetiology of breast cancer. Lancet (London, England), 1970, May-30, Volume: 1, Issue:7657 Topics: Adult; Age Factors; Animals; Asian People; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone;	1970
[Comparing metabolic studies following infusion of dehydroepiandrosterone sulfate and dehydroepiandrosterone phosphate]. Endokrinologie, 1965, Volume: 49, Issue:1 Topics: 17-Ketosteroids; Adult; Androgens; Androsterone; Breast Neoplasms; Dehydroepiandrosterone; Estradiol	1965
[Comparing metabolic studies following infusion of delta-4-androstene-3,17-dione, testosterone phosphate and dehydroepiandrosterone phosphate]. Endokrinologie, 1965, Volume: 49, Issue:1 Topics: 17-Ketosteroids; Adult; Androgens; Androsterone; Breast Neoplasms; Dehydroepiandrosterone; Estradiol	1965
Clinical investigative activities of the Eppley Cancer Institute. 3. The Nebraska state medical journal, 1968, Volume: 53, Issue:4 Topics: Breast Neoplasms; Chromium Isotopes; Cytodiagnosis; Estriol; Female; Gastrointestinal Neoplasms; Hum	1968
Steroid metabolism by human breast tumours. The Biochemical journal, 1970, Volume: 116, Issue:5 Topics: 17-Ketosteroids; Androstanes; Breast Neoplasms; Chromatography, Thin Layer; Dehydroepiandrosterone;	1970
Increase in urinary excretion of oestrogen on administration of dehydroepiandrosterone sulphate to an adrenalectomized, oophorectomized patient with breast cancer. Steroidologia, 1971, Volume: 2, Issue:1 Topics: Adrenalectomy; Adult; Breast Neoplasms; Castration; Chromatography; Dehydroepiandrosterone; Estradio	1971
Androgen production and conversion to estrogens in normal postmenopausal women and in selected breast cancer patients. The Journal of clinical endocrinology and metabolism, 1973, Volume: 37, Issue:1 Topics: 17-Ketosteroids; Aged; Androgens; Androstenedione; Androsterone; Breast Neoplasms; Carbon Isotopes;	1973
[The mechanism of action of hydrocortisone administered by lumbar puncture in breast cancer]. Voprosy onkologii, 1973, Volume: 19, Issue:9 Topics: 11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Aged; Androsterone; Br	1973
Endogenous steroid concentrations in human breast tumours determined by high-resolution mass fragmentography. The Biochemical journal, 1974, Volume: 139, Issue:2 Topics: Androsterone; Breast Neoplasms; Chromatography, Gas; Dehydroepiandrosterone; Estradiol; Estriol; Est	1974
Specific estrogen binding by the cytoplasm fof human breast carcinoma. The Journal of clinical endocrinology and metabolism, 1970, Volume: 30, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Binding Sites; Breast Neoplasms; Carcinoma, I	1970
Carcinoma of the breast during estrogen replacement therapy. Cancer, 1972, Volume: 29, Issue:3 Topics: Adult; Aged; Breast Diseases; Breast Neoplasms; Carcinoma; Carcinoma, Intraductal, Noninfiltrating;	1972
The steroid specificity of the estrogen-receptor of human breast carcinoma. Journal of steroid biochemistry, 1974, Volume: 5, Issue:2 Topics: Androstanes; Androstenols; Binding Sites; Breast; Breast Neoplasms; Carcinoma; Cytosol; Dehydroepian	1974
Editorial: Some newer endocrine aspects of breast cancer. The New England journal of medicine, 1974, Dec-05, Volume: 291, Issue:23 Topics: Asian People; Breast Neoplasms; China; Estriol; Estrogens; Female; Humans; Japan; Parity; Receptors,	1974
Estrogen receptors and the estrone hypothesis in relation to endometrial and breast cancer. Gynecologic oncology, 1974, Volume: 2, Issue:2-3 Topics: Animals; Binding, Competitive; Breast Neoplasms; Centrifugation, Density Gradient; Endometrium; Estr	1974
Estrogen profiles of Oriental and Caucasian women in Hawaii. The New England journal of medicine, 1974, Dec-05, Volume: 291, Issue:23 Topics: Adolescent; Adult; Age Factors; Asian People; Breast Neoplasms; China; Estradiol; Estriol; Estrogens	1974
A comparative study of urinary oestrogens in the cancer of breast and prostate. Indian journal of cancer, 1974, Volume: 11, Issue:2 Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Male; Middle	1974
Urine oestrogen profiles of Asian and North American women. International journal of cancer, 1974, Aug-15, Volume: 14, Issue:2 Topics: Adolescent; Adult; Age Factors; Body Weight; Breast Neoplasms; Canada; Corpus Luteum; Estradiol; Est	1974
L-Dopa effect on prolactin, follicle-stimulating hormone, and luteinizing hormone in women with advanced breast cancer: a preliminary report. American journal of obstetrics and gynecology, 1972, Sep-15, Volume: 114, Issue:2 Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Bone Neoplasms; Breast Neoplasms; Dihydroxyphenyl	1972
[Urinary estrogen excretion in preneoplastic breast diseases]. Voprosy onkologii, 1972, Volume: 18, Issue:10 Topics: Adenofibroma; Adult; Breast Diseases; Breast Neoplasms; Circadian Rhythm; Estradiol; Estriol; Estrog	1972
Urinary estrogen excretion in men with breast cancer. The New England journal of medicine, 1973, Jul-19, Volume: 289, Issue:3 Topics: Adult; Aged; Breast Neoplasms; Chromatography, Thin Layer; Estradiol; Estriol; Estrogens; Estrone; H	1973
Male breast cancer. II. Metabolism of oestradiol-17 beta in men with breast cancer. Journal of steroid biochemistry, 1973, Volume: 4, Issue:5 Topics: Aged; Breast Neoplasms; Chromatography, Gas; Chromatography, Thin Layer; Estradiol; Estriol; Estroge	1973
Summary and recommendations of the workshop on breast cancer. Cancer, 1974, Volume: 33, Issue:6 Topics: Animals; Breast; Breast Neoplasms; Community Health Services; Estriol; Exudates and Transudates; Fem	1974
The study of the excretion of estrogens in patients with breast cancer treated with androgens. Neoplasma, 1972, Volume: 19, Issue:4 Topics: Adult; Androgens; Breast Neoplasms; Castration; Estradiol; Estriol; Estrogens; Estrone; Female; Huma	1972
Genetic predisposition to carcinoma of the breast: multiple human genotypes for estrogen 16 alpha hydroxylase activity in Caucasians. Journal of surgical oncology, 1972, Volume: 4, Issue:3 Topics: Breast Diseases; Breast Neoplasms; Estradiol; Estriol; Estrone; Female; Genital Neoplasms, Female; G	1972
Extraction of radioactive estrogens and metabolites from small amounts of human or animal tissues excised following intravenous administration of 6,7-3H-17beta-estradiol. The Journal of clinical endocrinology and metabolism, 1971, Volume: 33, Issue:4 Topics: Adipose Tissue; Breast Neoplasms; Chemical Precipitation; Chromatography, Thin Layer; Crystallizatio	1971
Breast cancer and interstitial-cell tumor in a patient with Klinefelter's syndrome. Cancer, 1969, Volume: 24, Issue:5 Topics: Aged; Breast Neoplasms; Carcinoma; Estriol; Humans; Karyotyping; Klinefelter Syndrome; Leydig Cell T	1969
Endocrinology and epidemiology of breast cancer. Cancer, 1969, Volume: 24, Issue:6 Topics: Breast Neoplasms; Estriol; Estrogens; Female; Humans; Menopause; Menstruation; Ovary; Pregnancy	1969
[Examination of the luteotropic hormone activity of blood and urinary steroid excretion in diseases of the breast]. Archiv fur Geschwulstforschung, 1969, Volume: 34, Issue:2 Topics: 17-Ketosteroids; Adenofibroma; Adolescent; Adult; Aged; Animals; Breast Diseases; Breast Neoplasms;	1969
Oestradiol production rates in man before and after orchiectomy for cancer. The Journal of endocrinology, 1970, Volume: 46, Issue:1 Topics: Aged; Breast Neoplasms; Castration; Estradiol; Estriol; Estrone; Humans; Male; Middle Aged; Prostati	1970
Abnormal estrogen metabolism and tissue estrogen receptor proteins in breast cancer. Cancer, 1970, Volume: 25, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Nucleus; Estradiol; Estriol; Estrogen Ant	1970
A method for the separation of polar androgens from estrogens. Analytical biochemistry, 1970, Volume: 34, Issue:2 Topics: Adrenal Glands; Adrenalectomy; Androgens; Breast Neoplasms; Carbon Isotopes; Castration; Countercurr	1970
Relationship between hormonal cytology and steroid excretion in post-menopausal women. The Journal of endocrinology, 1970, Volume: 48, Issue:4 Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Aged; Androsterone; Breast Neoplasms; Estriol; Estrogens	1970
Studies on the human metabolism of 6:7 3 H oestradiol. Steroidologia, 1970, Volume: 1, Issue:3 Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Estradiol; Estriol; Estrone; Female; Humans; Male;	1970
Peripheral metabolism of 3H-estradiol and the excretion of endogenous estrone and estriol glucosiduronate in women with breast cancer. The Journal of clinical endocrinology and metabolism, 1971, Volume: 33, Issue:1 Topics: Adult; Aged; Breast Neoplasms; Carbon Isotopes; Chromatography, Paper; Crystallization; Estradiol; E	1971
Oestrogen as a reticuloendothelial stimulant in patients with cancer. British medical journal, 1971, May-15, Volume: 2, Issue:5758 Topics: Breast Neoplasms; Bronchial Neoplasms; Diethylstilbestrol; Estriol; Estrogens; Ethinyl Estradiol; Fe	1971
[Role of estrogens in breast tumors]. Nihon Naibunpi Gakkai zasshi, 1967, Sep-20, Volume: 43, Issue:6 Topics: Adenofibroma; Breast Neoplasms; Chromatography; Estradiol; Estriol; Estrogens; Estrone; Humans; In V	1967
Influence of estradiol and estriol on urinary excretion of hydroxyproline in man. The Journal of laboratory and clinical medicine, 1968, Volume: 71, Issue:1 Topics: Acromegaly; Adult; Aged; Breast Neoplasms; Creatinine; Estradiol; Estriol; Estrogens; Female; Growth	1968
Effect of clomiphene citrate upon pituitary gonadotropins. Clomiphene and pituitary gonadotropins. American journal of obstetrics and gynecology, 1968, Feb-15, Volume: 100, Issue:4 Topics: Adult; Breast Neoplasms; Castration; Clomiphene; Cobalt Isotopes; Estradiol; Estriol; Estrone; Femal	1968
Metabolism of estriol-17alpha-3H in man. Steroids, 1968, Volume: 11, Issue:3 Topics: Aged; Breast Neoplasms; Carbon Isotopes; Estranes; Estriol; Female; Humans; Liver Cirrhosis; Male; M	1968
[The urinary excretion of estrogens in patients with far advanced breast cancer during treatment with prednisolone]. Voprosy onkologii, 1968, Volume: 14, Issue:12 Topics: Adrenal Glands; Breast Neoplasms; Castration; Chromatography; Estradiol; Estriol; Estrogens; Estrone	1968
Isolation and identification of estriol in urine of castrated and adrenalectomized women receiving 4-14C-testosterone. Steroids, 1968, Volume: 12, Issue:5 Topics: Adrenal Glands; Adrenalectomy; Breast Neoplasms; Carbon Isotopes; Castration; Chromatography, Paper;	1968
Estrogen metabolism in postmenopausal women with primary and recurrent breast cancer. European journal of cancer, 1968, Volume: 4, Issue:5 Topics: Aging; Breast Neoplasms; Estradiol; Estriol; Estrogens; Estrone; Female; Humans; Menopause; Middle A	1968

estriol and Breast Neoplasms